聚多巴胺介导的生物界面纳米酶作为IBD治疗中的益生菌保护涂层
Tong Zhang1, Chen Wang2, Ting Du2
1College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi 712100, China; Northwest A&F University Shenzhen Research Institute, Shenzhen, Guangdong 518000, China.
International journal of biological macromolecules
|April 1, 2025
概括
这项研究开发了一种新的益生菌纳米涂层,显著提高了它们的生存率和治疗炎症性肠病 (IBD) 的有效性. 增强的益生菌促进肠道屏障的修复,并恢复健康的肠道微生物群平衡.
科学领域:
- 生物技术和生物医学工程 生物技术和生物医学工程
- 胃肠病学 胃肠病学
- 材料科学 材料科学 材料科学
背景情况:
- 炎症性肠病 (IBD) 的特点是肠道屏障功能障碍和肠道微生物群的失调.
- 益生菌显示IBD的治疗潜力,但患有低活力和胃肠道粘附性差.
- 现有的挑战需要创新的策略来提高益生菌的输送和IBD治疗的疗效.
研究的目的:
- 设计和评估益生菌的专用纳米涂层,以改善其在IBD中的生存和治疗效果.
- 研究纳米涂层益生菌的粘粘性,ROS清除性和胃肠道耐受性.
- 评估纳米涂层益生菌在改善IBD症状和恢复肠道微生物群平衡中的有效性.
主要方法:
- 使用生物界面组件和纳米酶开发一种保护性纳米涂层 (PDA@CeO2),用于Bifidobacterium bifidum (BB. ) 的情况.
- 使用XRD,SEM和TEM进行纳米涂层附着的表征.
- 在模拟的胃液中评估益生菌生存率和IBD小鼠模型中的治疗效果,包括肠道屏障修复和微生物群分析.
主要成果:
- 这种PDA@CeO2纳米涂层显著增强了BBB. 在模拟的胃液中生存率 (比无保护的BB高9.4倍). ) 的情况.
- 有纳米涂层的BBB. 在复杂的胃肠道环境中表现出优异的粘粘度,ROS清除活性和耐受性.
- 在IBD小鼠模型中,PDA@CeO2-B.B.B. 治疗促进了肠道屏障的修复和调节肠道微生物群的组成,减少了疾病的复发.
结论:
- 保护性纳米涂层的有针对性的设计可以显著提高IBD治疗的益生菌功能.
- 在PDA@CeO2涂层的BBB. 为改善IBD的肠道屏障完整性和微生物群平衡提供了一个有希望的策略.
- 这种方法有可能开发基于益生菌的先进疗法来治疗炎症性肠病.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
259
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
259
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110
Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126
Drugs for Treatment of Constipation-Predominant IBS
117
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109


